Current indications for low-molecular-weight heparins;Indications actuelles des heparines de bas poids moleculaire

Annales de Medecine Interne

Volumn 148, Issue 2, 1997, Pages 154-162

  Vignes, Stéphane ^a   Meyer, Guy ^b   Marjanovic, Zora ^a   Farge Bancel, Dominique ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Hopital Laennec   (France)

Author keywords

low molecular weight heparin; venous thromboembolic disease

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; LUNG EMBOLISM; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; FEMALE; MALE; POSTOPERATIVE COMPLICATION; PREGNANCY; REVIEW; THROMBOEMBOLISM; THROMBOPHLEBITIS;

CEREBROVASCULAR DISORDERS; CORONARY DISEASE; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PREGNANCY; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0030912668     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. THOMAS DP : Annotation. Heparin, low molecular weight heparin, and heparin analogies. Br J Haematol 1984 ; 58 : 385-90.
2. SCHAFER AI : Low-molecular-weight heparin. An opportunity for home treatment of venous thrombosis. N Engl J Med 1996 ; 334 : 724-5.
3. BERGQVIST D : Low molecular weight heparin. J Intern Med 1996 ; 240 : 63-72.
4. BARROWCLIFFE TW : Annotation. Low molecular weight heparin(s). Br J Haematol 1995 ; 90 : 1-7.
5. LANE DA, DENTON J, FLYNN AM, THUNBERG I, LINDAHL U : Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984 ; 218 : 725-32.
6. HULL RD, RASKOB GE, HIRSH J : Prophylaxis of venous thromboembolism : an overview. Chest 1986 ; 89 (suppl) : 374-83S.
7. LINDBLAD B, STERNBY N, BERGQVIST D : Incidence of venous thrombosis verified by necropsy over 30 years. Br Med J 1991 ; 302 : 709-11.
8. COUTURAUD F, LEROYER C, LE MOIGNE E, OGER E, MOTTIER D : Prévention de la thrombose veineuse profonde en milieu médical. Presse Med 1996 ; 25 : 1935-40.
9. MEYER G, FARGE D, SAUVAGET F et al : Maladie thromboembolique et cancer. Presse Med 1994 ; 23 : 1767-71.
10. COLDITZ G, TUDEN R, OSTER G : Rates of venous thrombosis after general surgery. Combined results of randomized clinical trials. Lancet 1986 ; ii : 143-6.
11. COLLINS R, SCRIMGEOUR A, YUSUF S, PETO R : Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988 ; 318 : 1162-72.
12. CLAGETT P, REISCH J : Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988 ; 208 : 227-40.
13. KAKKAR VV : Efficacy and safety of clivarin and other LMWHs in general surgery : a meta-analysis. Blood Coagul Fibrinolysis 1993 ; 4 : S23-7.
14. IMPERIALE TF, SPEROFF T : A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994 ; 271 : 1780-5.
15. LEIZOROVICZ A, HAUGH MC, CHAPUIS ER, SAMAMA MM, BOISSEL JP : Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992 ; 305 : 913-20.
16. NURMOHAMED MT, ROSENDAAL FR, BÜLLER HR et al : Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery : a meta-analysis. Lancet 1992 ; 340: 152-6.
17. NICOLAIDES AN, BERGQVIST D, BURMARK US et al : European Consensus Statement. Prevention of venous thromboembolism. Int Angiol 1992 ; ii : 151-9.
18. TRYBA M und die Teilnehmer des Workshop über hämostaseologische Probleme bei Regionalanaesthesien. Haemostaseologische Voraussetzungen zur Durch-führung von Regionalanaesthesien. Regional-Anaesthesie 1989 ; 12 : 127-31.
19. BERGQVIST D, LINDBLAD B, MATZSCH T : Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia-is there a risk ? Acta Anaesthesiol Scand 1992 ; 36 : 605-9.
20. GARDLUNG B : Randomized, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996 ; 347 : 1357-61.
21. HARENBERG J, KALLENBACH B, MARTIN U et al : Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990 ; 59 : 639-50.
22. PONIWIESKI M, BARTHELS M, KUHN M, POLIWODA H : Uber die Wirksamkeit niedermolekularen heparins (Fragmin) in der Thromboembolieprophylaxe bei internitischen Patienten : eine randomisierte Doppelblindstudie. Med Klin 1988; 83 : 241-5.
23. AQUINO JP, GAMBIER A, DUCROS JJ : Prevention of thromboembolic accidents in elderly sujects with Fraxiparine. In : Bounameaux H, Samama M, ten Cate JW, eds. Fraxiparine second international symposium. Recent pharmacological and clinical data. New York : Schattauer Thromb Haemost, 1990 : 51-4.
24. MANCIET G, VERGNES C, VAISSIÉ JJ, BOISSEAU MR : A study on the efficacy and tolerance of Fraxiparine during long-term therapy of the elderly : a randomized double-blind trial. In : BOUNAMEAUX H, SAMAMA M, TEN CATE JW, eds. Fraxiparine second international symposium. Recent pharmacological and clinical data. New York : Schattauer Thromb Haemost, 1990 : 55-9.
25. LECHLER E, SCHRAMM W, FLOSBACH CW, for the PRIME Study Group : The venous thrombotic risk in non-surgical patients : epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin) : Haemostasis 1996 ; 26 (suppl 2) : 49-56.
26. MOTTIHR D, for Geriatric Enoxaparin Study Group : Prophylaxis of deep venous thrombosis in medical geriatric patients (abstract 2045). Thromb Haemost 1993 ; 69 : S1115.
27. THRIFT. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992 ; 305 : 567-74.
28. SCATI (Studio Sulla Calciparina Nell'Angina E Nella Thrombosi Ventricolare Nell'Infarcto) Group : Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989 ; ii : 183-6.
29. PRINS MH, GELSEMA R, SING AK, VAN HEERDE LR, DEN OTTOLANDER GJH : Prophylaxis of deep-vein thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989 ; 19 : 245-50.
30. SANDSET PM, DAHL T, STIRIS M, ROSTAD B, SCHEEL B, ABILDGAARD U : A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990 ; 16S : 25-33.
31. GEERTS WH, JAY RM, CODE KI et at : A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996 ; 335 : 701-7.
32. GREEN D, LEE MY, LIM AC et al : Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990 ; 113 : 571-4.
33. HJELMSTEDT A, BERGVALL U : Phlebographic study of the incidence of thrombosis in the injured and uninjured limb in 55 cases of tibial fracture. Acta Chir Scand 1968 ; 134 : 229-34.
34. Consensus Conference Prevention of venous thrombosis and pulmonary embolism : JAMA 1986 ; 256 : 744-9.
35. SPANNAGEL U, KUJATH P : Low molecular weight heparin for the prevention of thromboembolism in outpatients immobilized by plaster cast. Semin Thromb Hemost 1993 ; 19 : S131-41.
36. LEIZOROVICZ A, SIMONNEAU G, DECOUSUS H, BOISSEL JP : Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis. Br Med J 1994 ; 309 : 299-303.
37. LENSING AWA, PRINS MH, DAVIDSON BL, HIRSH J : Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995 ; 155 : 601-7.
38. GREEN D, HIRSH J, HEIT J, PRINS M, DAVIDSON B, LENSING AWA : Low molecular weight heparin : a critical analysis of clinical trials. Pharmacol Rev 1994 ; 46 : 89-109.
39. ALHENC-GELAS M, JESTIN-LE GUERNIC C, VITOUX JF, KHER A, AIACH M, FIESSENGER JN : Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994 ; 71 : 698-702.
40. BONEU B : Low molecular weight heparin therapy : is monitoring needed. Thromb Haemost 1994 ; 72 : 330-4.
41. KOOPMAN MMW, PRANDONI P, PIOVELLA F et al : Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996 ; 334 : 682-7.
42. LEVINE M, GENT M, HIRSH J et al : A comparison of low-molecular-weight heparin administered primarily at home with unfractioned heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996 ; 334 : 677-81.
43. HULL RD, RASKOB GE, PINEO GF et al : Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992 ; 326 : 975-82.
44. FIESSINGER JN, LOPEZ-FERNANDEZ M, GATTERER E et al : Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996 ; 76 : 195-9.
45. THERY C, SIMONNEAU G, MEYER G et al : Randomized trial of subcutaneous low molecular weight heparin CY216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose ranging study. Circulation 1992 ; 85 : 1380-9.
46. HUET Y, GOUAULT-HEILMANN M, CONTANT G, BRUN-BUISSON C : Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study. Intensive Care Med 1987 ; 13 : 126-30.
47. MEYER G, BRENOT F, PACOURET G et al : Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism : an open randomized pilot study. Thromb Haemost 1995 ; 68 : 95-6.
48. The RISC Group : Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet 1990 ; 336 : 827-30.
49. MELANDRI G, SEMPRINI F, CERVI V : Comparison of efficacy of low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation 1993 ; 88 : 2517-23.
50. GURFINKEL, P, MANOS EJ, MEFAIL RI et al : Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995 ; 26: 313-8.
51. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group : Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996 ; 347 : 561-8.
52. GLICK A, KORNOWSKI R, MICHOWICH Y et al : Reduction of infarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996 ; 77: 1145-8.
53. MATTHIASSON S, BERGQVIST D, LUNDELL A, LINDBLAD B : Effect of dextran and enoxaparin on early ePTPE graft thrombogenicity in sheep. Eur J Vasc Endovasc Surg 1995 ; 9 : 284-92.
54. HANKE H, OBERHOFF M, HANKE S et al : Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular weight-heparin. Circulation 1992 ; 85 : 1548-56.
55. FAXON DP, SPIRO TE, MINOR S et al : Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis trial. Circulation 1994 ; 90 : 908-14.
56. EDMONDSON RA, COHEN AT, DAS SK, WAGNER MB, KAKKAR VV : Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994 ; 344 : 914-8.
57. SAMAMA CM, COMBE S, ILL P, BARRE E, DREUX S, VIARS P : Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi ? Haemostasis 1996 ; 26 (suppl 2) : 57-64.
58. KAY R, WONG KS, YU YL et al : Low-molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1996 ; 333 : 1588-93.
59. NURMOHAMMED MT, BÜLLER HR, TEN CATE JW : Low molecular weight heparins in extracorporeal circuits. In : Bounameaux H, ed. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York : Marcel Dekker Inc, 1994 : 247-71.
60. SCHMITT Y, SCHNEIDER H : Low-molecular-weight heparin (LMWH) : influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993 ; 8 : 438-52.
61. KRONENBERG F, KONIG P, NEYER U et al : Influence of various heparin preparations on lipoproteins in hemodialysis patients : a multicentre study. Thromb Haemost 1995 ; 74 : 1025-8.
62. HARENBERG J, SCHNEIDER D, HEILMANN L, WOLF H : Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993 ; 23 : 314-20.
63. DULITZKI M, PAUZNER R, LANGEVITZ P, PRAS M, MANY A, SCHIFF E : Low-molecular-weight heparin during pregnancy and delivery : preliminary experience with 41 pregancies. Obstet Gynecol 1996 ; 87 : 380-3.
64. RASMUSSEN C, WADT J, JACOBSEN B : Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int J Gynaecol Obstet 1994 ; 47 : 121-5.